Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Addictive disorders & their treatment
| Addictive disorders & their treatment |
| Pubbl/distr/stampa | Hagerstown, MD, : Lippincott Williams & Wilkins |
| Descrizione fisica | 1 online resource (20 volumes) |
| Disciplina | 362 |
| Soggetto topico |
Substance abuse - Treatment
Substance abuse Substance-Related Disorders - therapy Substance-Related Disorders Polytoxicomanie - Traitement Polytoxicomanie Toxicomanie Abús de substàncies Drogoaddicció Terapèutica |
| Soggetto genere / forma |
Periodical
Periodicals. Revistes electròniques. |
| ISSN | 1535-1122 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Addictive disorders and their treatment |
| Record Nr. | UNINA-9910763987003321 |
| Hagerstown, MD, : Lippincott Williams & Wilkins | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in Cancer Treatment : From Systemic Chemotherapy to Targeted Therapy / / by Iago Dillion Lima Cavalcanti, José Cleberson Santos Soares
| Advances in Cancer Treatment : From Systemic Chemotherapy to Targeted Therapy / / by Iago Dillion Lima Cavalcanti, José Cleberson Santos Soares |
| Autore | Cavalcanti Iago Dillion Lima |
| Edizione | [1st ed. 2021.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2021 |
| Descrizione fisica | 1 online resource (VIII, 109 p. 27 illus., 25 illus. in color.) |
| Disciplina | 616.994 |
| Soggetto topico |
Oncology
Internal medicine Pharmacy Cancer—Treatment Tumor markers Cancer Nanomedicine Internal Medicine Cancer Therapy Tumour Biomarkers Cancer Nanotechnology Oncologia Terapèutica Fisiologia patològica Nanomedicina |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-68334-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Cancer: concepts and epidemiology -- A brief history of cancer -- What is Cancer? -- Cancer Epidemiology -- Cancer development and immunology -- Cell cycle -- Cell cycle control: the function of cyclins -- Cancer triggering agents -- Proto-oncogenes -- Tumor suppressor genes -- Development of tumor mass -- Cancer Immunology -- Discovery of tumor markers -- Cancer diagnosis -- Impact of the discovery of tumor markers -- Main tumor markers for cancer diagnosis -- Alpha-fetoprotein (AFP) -- Human Chorionic Gonadotropin (β-HCG) -- Mucin-like cancer-associated antigen (MCA) -- CA 15.3 -- Carcinoembryonic antigen (CEA) -- Bladder tumor antigen (BTA) -- Telomerase -- Nuclear matrix protein (NMP 22) -- Cyfra 21.1 -- Prostatic acid phosphatase (PAP) -- Prostate-specific antigen (PSA) -- CA 125 -- CA 19.9 -- p53 -- CA 72.4 -- K-ras -- HER2 -- Cancer staging -- Conventional cancer treatment -- Therapeutic modalities of cancer -- Surgery -- Radiotherapy -- Antineoplastic chemotherapy -- Classification of antineoplastic agents by cycle -- Specific cycle antineoplastics -- Nonspecific antineoplastic agents -- Classification of antineoplastic agents by chemical structure and function -- Alkylating agents -- Antimetabolites -- Plant-derived antineoplastics -- Antitumor antibiotics -- Chemotherapy toxicity -- Hematological toxicity -- Liver toxicity -- Cardiac toxicity -- Anthracyclines -- Fluoropyrimidine -- Taxanes -- Pulmonary toxicity -- Neurological toxicity -- Renal toxicity -- Gastrointestinal toxicity -- Metabolic changes -- Targeted therapies in cancer treatment -- Overexpressed receptors on tumor cells -- Immunotherapy -- Monoclonal antibodies -- Types of monoclonal antibodies -- Side effects of monoclonal antibodies -- Checkpoint Inhibitors -- Side effects of checkpoint inhibitors -- Cancer Vaccines -- Vaccines in cancer prevention -- Vaccines for the treatment of cancer -- Non-specific immunotherapies -- Tyrosine kinase inhibitors -- Imatinib -- Gefitinib -- Erlotinib -- Sorafenib -- Dasatinib -- Nilotinib -- Lapatinib -- Adverse events of tyrosine kinase inhibitors -- Conventional chemotherapy vs. targeted therapy -- Differences between conventional chemotherapy and targeted therapy -- Risks and benefits of conventional chemotherapy compared to targeted therapy -- Eligibility criteria for the indication of the targeted therapy -- Side effects of targeted therapy -- Can targeted therapy replace conventional chemotherapy? -- Targeted therapy associated with conventional chemotherapy -- Pharmaceutical nanotechnology applied to cancer -- Pharmaceutical nanotechnology -- Classification of nanosystems -- Liposomes -- Micelles -- Polymeric nanoparticles -- Solid lipid nanoparticles -- Magnetic nanoparticles -- Metal nanoparticles -- Main functions of nanosystems in cancer -- Pharmaceutical nanotechnology in cancer diagnosis -- Pharmaceutical nanotechnology for cancer treatment. |
| Record Nr. | UNINA-9910484989203321 |
Cavalcanti Iago Dillion Lima
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Advances in physiotherapy
| Advances in physiotherapy |
| Pubbl/distr/stampa | [Oslo, Norway] : , : Scandinavian University Press, , [1999-2012] |
| Descrizione fisica | 1 online resource |
| Disciplina | 615.82 |
| Soggetto topico |
Therapeutics, Physiological
Physical therapy Physical Therapy Modalities Therapeutics Physiothérapie Médecines parallèles Terapèutica Terapèutica fisiològica Fisioteràpia |
| Soggetto genere / forma |
Periodical
Periodicals. Revistes electròniques. |
| ISSN | 1651-1948 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910140518603321 |
| [Oslo, Norway] : , : Scandinavian University Press, , [1999-2012] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Applied research in quality of life
| Applied research in quality of life |
| Pubbl/distr/stampa | Dordrecht : , : International Society for Quality of Life Studies : , : Springer, , 2006- |
| Disciplina | 306 |
| Soggetto topico |
Quality of life - Research
Social indicators Happiness Applied sociology Qualité de la vie Quality of life Rehabilitation Therapeutics Quality of Life Sociology Qualitat de vida Terapèutica |
| Soggetto genere / forma |
Periodical
Periodicals. Revistes electròniques |
| ISSN | 1871-2576 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | ARQOL |
| Record Nr. | UNINA-9910144512203321 |
| Dordrecht : , : International Society for Quality of Life Studies : , : Springer, , 2006- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Archivum immunologiae et therapiae experimentalis
| Archivum immunologiae et therapiae experimentalis |
| Pubbl/distr/stampa | Basel, : Birkhaüser |
| Disciplina | 616.079 |
| Soggetto topico |
Immunology
Therapeutics, Experimental Allergy and Immunology Therapeutics Immunologie Thérapeutique expérimentale Thérapeutique treating (health care function) Al·lèrgia Immunologia Terapèutica |
| Soggetto genere / forma |
Periodical
periodicals. Periodicals. Périodiques. Revistes electròniques. |
| ISSN | 1661-4917 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | AITE |
| Record Nr. | UNINA-9910143376803321 |
| Basel, : Birkhaüser | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Asthma : pathophysiology, herbal and modern therapeutic interventions / / Sheikh Rayees, Inshah Din
| Asthma : pathophysiology, herbal and modern therapeutic interventions / / Sheikh Rayees, Inshah Din |
| Autore | Rayees Sheikh |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (ix, 69 pages) : illustrations |
| Disciplina | 616.23807 |
| Collana | SpringerBriefs in Immunology |
| Soggetto topico |
Asthma - Pathophysiology
Asma Fisiologia patològica Terapèutica Farmàcia homeopàtica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-70270-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Introduction -- Contents -- Chapter 1: Asthma -- Chapter 2: Types of Asthma -- 2.1 Mild to Moderate Asthma -- 2.2 Severe Asthma -- 2.3 Pathophysiology Asthma -- 2.4 Interleukin-5 -- 2.5 Interleukin-13 -- 2.6 Interleukin-4 -- Chapter 3: Airway Inflammation and Airway Hyperresponsiveness -- Chapter 4: Effects of Inflammation -- 4.1 Effects on Airway Epithelia -- 4.2 Fibrosis -- 4.3 Mucus Hypersecretion -- 4.4 Airway Smooth Muscle -- Chapter 5: Inflammatory Cells Involved in Asthma -- 5.1 Eosinophils -- 5.2 Mast Cells -- 5.3 Macrophages -- 5.4 Dendritic Cells -- 5.5 CD4+T Cells -- 5.5.1 Activation and Differentiation -- 5.5.2 Th2 Cells and Asthma -- Chapter 6: Transcription Factors Involved in Th2 Cell Differentiation -- Chapter 7: Current Asthma Treatments -- 7.1 Inhaled Corticosteroids -- 7.2 Adverse Effects -- 7.3 Leukotriene Antagonists -- 7.4 Adverse Effects -- 7.5 Short-Acting Beta2 Agonists -- 7.6 Adverse Effects -- 7.7 Long-Acting Beta2 Agonists -- 7.8 Adverse Effects -- 7.9 Phosphodiesterase Inhibitors and Methylxanthines -- 7.10 Adverse Effects -- 7.11 Anticholinergics (Anti-muscarinic) -- 7.12 Adverse Effects -- Chapter 8: Cytokine-Based Therapies -- 8.1 Anti-IL-9 Therapy -- 8.2 Anti-IL-13 Therapy -- 8.3 Anti-IL-4 Therapy -- 8.4 Anti-IL-17 Therapy -- 8.5 Anti-IgE Therapy -- 8.6 Anti-IL-5 Therapy -- 8.7 Anti-TSLP -- Chapter 9: Transcription Factor Modulators -- 9.1 STAT6 -- 9.2 GATA3 -- 9.3 NF-κB and AP-1 -- Chapter 10: Preclinical Mouse Models of Asthma Used to Evaluate Drug Efficacy and Properties and Associated Drawbacks -- Chapter 11: Herbal Treatments of Asthma -- Chapter 12: Traditional Plants with Anti-asthmatic Potential -- Chapter 13: Asthma Chinese Herbal Remedies -- 13.1 Anti-asthma Herbal Medicine Intervention (ASHMI) -- 13.2 Modified Mai Men Dong Tang (mMMDT) -- 13.3 Ding Chuan Tang -- 13.4 STA-1.
13.5 Sophora flavescens Ait -- 13.6 Ma Huang -- 13.7 Minor Blue Dragon -- 13.8 Ginkgo biloba -- 13.9 Ginseng -- 13.10 Liquorice -- 13.11 Zizyphi fructus and Zizyphus jujuba -- 13.12 Cinnamon -- 13.13 Blipleuru -- 13.14 Sckisandra Ckintvisis -- 13.15 Ligusticum wallichii -- 13.16 Other Herbs -- Chapter 14: Future Potential of Herbal-Based Medicinal Treatment for Management of Asthma -- References. |
| Record Nr. | UNINA-9910484355303321 |
|
Rayees Sheikh
|
||
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Behavioral sleep medicine : a practical guide for adult and pediatric providers / / Lisa Medalie ; with contributions by David Gozal and Kathryn Hansen ; foreword by Hrayr Attarian
| Behavioral sleep medicine : a practical guide for adult and pediatric providers / / Lisa Medalie ; with contributions by David Gozal and Kathryn Hansen ; foreword by Hrayr Attarian |
| Autore | Medalie Lisa |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (128 pages) |
| Disciplina | 616.89142 |
| Soggetto topico |
Behavior therapy
Sleep disorders Sleep disorders in children Trastorns del son Terapèutica Teràpia de la conducta |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-031-12574-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Foreword -- Introduction -- Acknowledgments -- Contents -- 1: Cognitive Behavioral Treatment for Insomnia -- 1.1 Visit 1: Intake and Sleep Hygiene -- 1.1.1 Provider Intake Form -- 1.1.2 Intake Script -- 1.1.3 Sleep Hygiene Clinic Talking Points -- 1.1.4 Sleep Hygiene Patient Handout -- 1.1.5 Chronic Insomnia Diagnostic Criteria -- Chronic Insomnia Disorder -- 1.1.6 Short-Term Insomnia Diagnostic Criteria -- Short-Term Insomnia Disorder -- Alternate Names -- 1.1.7 Other Insomnia Disorder Diagnostic Criteria -- Other Insomnia Disorder -- 1.1.8 Cognitive Behavioral Treatment for Insomnia Sleep Log -- 1.1.9 Weekly Questionnaire for Cognitive Behavioral Treatment for Insomnia Sessions -- 1.1.10 Sleep Hygiene Reading List -- 1.2 Visit 1 Add-on (As Needed): Sleep Medication Taper -- 1.2.1 Medication Taper Clinic Talking Points -- 1.2.2 Sleep Medication Taper Patient Handout -- 1.2.3 Sleep Medication Taper Reading List -- 1.3 Visit 2: Stimulus Control and Sleep Restriction -- 1.3.1 Behavioral Sleep Medicine Follow-up Form -- 1.3.2 Stimulus Control Clinic Talking Points -- 1.3.3 Stimulus Control Patient Handout -- 1.3.4 Stimulus Control Reading List -- 1.3.5 Sleep Restriction Clinic Talking Points -- 1.3.6 Sleep Restriction Patient Handout -- 1.3.7 Sleep Restriction Reading List -- 1.4 Visit 3: Relaxation Strategies -- 1.4.1 Relaxation Strategies Clinic Talking Points -- 1.4.2 Relaxation Strategies Patient Handout -- 1.4.3 Relaxation Strategies Reading List -- 1.5 Visit 4: Worry-time -- 1.5.1 Worry-time Clinic Talking Points -- 1.5.2 Worry-time Patient Handout -- 1.5.3 Worry-time Reading List -- 1.6 Visit 5: Identifying Cognitive Errors -- 1.6.1 Identifying Cognitive Errors Clinic Talking Points -- 1.6.2 Identifying Cognitive Errors Patient Handouts -- 1.6.3 Common Cognitive Errors.
1.6.4 Identifying Cognitive Errors Questionnaire -- 1.7 Visit 6: Cognitive Restructuring -- 1.7.1 Cognitive Restructuring Clinic Talking Points -- 1.7.2 Cognitive Restructuring Patient Handout -- 1.7.3 Cognitive Restructuring Reading List -- 1.8 Visit 7: Maintenance and Relapse Prevention -- 1.8.1 Maintenance and Relapse Prevention Clinic Talking Points -- 1.8.2 Maintenance and Relapse Prevention Patient Handout -- Bibliography -- 2: Pediatric Behavioral Sleep Medicine -- 2.1 Visit 1: Intake and Sleep Hygiene -- 2.1.1 Provider Intake Form -- 2.1.2 Pediatric Sleep Hygiene Clinic Talking Points -- 2.1.3 Pediatric Sleep Hygiene Handout -- 2.1.4 Pediatric Sleep Log for Parents -- 2.1.5 Brief Sleep Screen for Pediatrics -- 2.1.6 Provider Notes Regarding Pediatric Treatment Plans -- 2.2 Pediatric Follow-up: Learning Independent Sleep -- 2.2.1 Standard and Graduated Extinction Clinic Talking Points -- 2.2.2 Standard Extinction Parent Handout -- 2.2.3 Graduated Extinction Parent Handouts -- 2.2.4 Standard and Graduated Extinction Reading List -- 2.2.5 Bedtime Pass Clinic Talking Points -- 2.2.6 Bedtime Pass Parent Handout -- 2.2.7 Bedtime Pass Reading List -- 2.2.8 Evening Schedule Clinic Talking Points -- 2.2.9 Evening Schedule Parent Handout -- 2.2.10 Evening Schedule/Bedtime Routine Reading List -- 2.2.11 Behavior Chart Clinic Talking Points -- 2.2.12 Behavior Chart Clinic Parent Handout -- 2.2.13 Behavior Chart Reading List -- Bibliography -- 3: Actigraphy -- 3.1 Actigraphy Clinic Talking Points -- 3.2 Actogram Example -- 3.2.1 Actogram -- 3.3 Actigraphy Reading List -- 4: CBT for CPAP Adherence -- 4.1 Visit 1: Intake and Treatment Planning -- 4.1.1 Initial Visit Clinic Talking Points -- 4.2 CPAP Intake Form -- 4.2.1 CPAP Adherence Barriers Guide -- 4.2.2 Obstructive Sleep Apnea, Adult Diagnostic Criteria. Obstructive Sleep Apnea, Adult -- 4.2.3 Obstructive Sleep Apnea, Pediatric Diagnostic Criteria -- Obstructive Sleep Apnea, Pediatric -- 4.3 CPAP Adherence Patient Handouts -- 4.3.1 Psychoeducation Patient Handout -- 4.4 CPAP Adherence Patient Handouts -- 4.4.1 Desensitization Patient Handout -- 4.5 CPAP Adherence Patient Handouts -- 4.5.1 Motivational Enhancement Patient Handout -- 4.6 CPAP Adherence Patient Handouts -- 4.6.1 Adherence Tracking -- 4.6.2 CPAP Adherence Reading List -- Bibliography -- 5: Imagery Rehearsal Therapy for Nightmare Disorder -- 5.1 Visit 1: Nightmare Intake and Psychoeducation -- 5.1.1 IRT Introduction Clinic Talking Points -- 5.1.2 Provider Guide to Comorbidities and Differentials -- 5.1.3 Imagery Rehearsal Therapy Intake Form -- 5.1.4 Nightmare Disorder Diagnostic Criteria -- Nightmare Disorder -- 5.1.5 Nightmare Psychoeducation Patient Handout -- 5.1.6 Imagery Rehearsal Therapy Tracking Form -- 5.1.7 Imagery Rehearsal Therapy Reading List -- 5.2 Visit 2: Positive Imagery -- 5.2.1 Positive Imagery Clinic Talking Points -- 5.2.2 Positive Imagery Reading List -- 5.3 Visit 3: Rescripting -- 5.3.1 Rescripting Clinic Talking Points -- 5.3.2 Rescripting Reading List -- 5.4 Visit 4: Rescripting Follow-up -- 5.4.1 Rescripting Follow-up Clinic Talking Points -- 5.5 Visit 5: Maintenance and Relapse Prevention -- 5.5.1 Maintenance and Relapse Prevention Clinic Talking Points -- Bibliography -- 6: Delayed Sleep Phase Syndrome -- 6.1 Provider Guide to Assessment -- 6.2 Delayed Sleep-Wake Phase Disorder Diagnostic Criteria -- 6.2.1 Delayed Sleep-Wake Phase Disorder -- 6.3 Circadian Rhythm Screening Tool -- 6.4 Delayed Sleep Phase Syndrome Clinic Talking Points -- 6.5 Delayed Sleep Phase Syndrome Sleep Hygiene Handout -- 6.6 Delayed Sleep Phase Syndrome Tracking. 6.7 Delayed Sleep Phase Syndrome Patient Handout -- 6.8 Delayed Sleep Phase Syndrome Reading List -- Bibliography -- 7: Night Eating Syndrome -- 7.1 Night Eating Syndrome Clinic Talking Points -- 7.2 Proposed Diagnostic Criteria for Night Eating Syndrome -- 7.3 Night Eating Questionnaire -- 7.4 Night Eating Syndrome Tracking -- 7.5 Night Eating Syndrome Patient Handout -- 7.6 Night Eating Syndrome Reading List -- Bibliography -- 8: Parasomnias -- 8.1 Parasomnias Clinic Talking Points -- 8.1.1 Psychoeducation -- 8.1.2 Triggers -- 8.1.3 Sleepwalking -- 8.1.4 Sleep Terrors -- 8.1.5 Sleep Enuresis -- 8.2 Sleepwalking Diagnostic Criteria -- 8.2.1 Sleepwalking -- 8.2.2 Alternate Names -- 8.2.3 Sleep Terrors Diagnostic Criteria -- Sleep Terrors -- Alternate Names -- 8.2.4 Sleep Enuresis Diagnostic Criteria -- Sleep Enuresis -- 8.2.5 Parasomnias Sleep Need Handout -- 8.2.6 Parasomnias Log -- 8.2.7 Parasomnias Reading List -- Bibliography -- 9: Society for Behavioral Sleep Medicine (SBSM) Resources -- 9.1 SBSM Resource List Link -- 9.2 Theories -- 9.2.1 Classic and Operant Conditioning -- 9.2.2 Shaping/Exposure -- 9.2.3 Reinforcement Schedules, Extinction, Spontaneous Recovery -- 9.2.4 Placebo Effect -- 9.2.5 Theories of Behavioral Change -- 9.2.6 Relaxation -- 9.2.7 Acceptance & -- Commitment Therapy / Mindfulness -- 9.2.8 Cognitive Restructuring -- 9.2.9 Behavioral Activation -- 9.3 Physiology -- 10: Behavioral Sleep Medicine Board Preparation -- 10.1 Becoming Certified -- 10.1.1 Requirements for Certification -- Eligibility Requirements for Examination -- 10.1.2 Frequently Asked Questions from the SBSM -- Who Is Eligible to Apply for DBSM Certification? -- What Disciplines Are Included as Eligible to Obtain a BSM Certification? -- Once I Obtain BSM Certification, Will I Need to Renew it?. Do I Need to Take the BSM Exam to Obtain a DBSM if I Am Already Credentialed in Sleep Medicine or Sleep Dentistry? -- Who Can I Contact to Get my Questions Answered About the BSM Exam? -- Index. |
| Record Nr. | UNINA-9910637733403321 |
|
Medalie Lisa
|
||
| Cham, Switzerland : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Biology and Treatment of Leukemia and Bone Marrow Neoplasms / / edited by Vinod Pullarkat, Guido Marcucci
| Biology and Treatment of Leukemia and Bone Marrow Neoplasms / / edited by Vinod Pullarkat, Guido Marcucci |
| Edizione | [1st ed. 2021.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2021 |
| Descrizione fisica | 1 online resource (200 pages) |
| Disciplina | 616.99 |
| Collana | Cancer Treatment and Research |
| Soggetto topico |
Hematology
Oncology Medicine - Research Biology - Research Biomedical Research Leucèmia mieloide Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-78311-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Advances in diagnosis and risk stratification of leukemias and bone marrow neoplasms -- Genetics and diagnostic approach to lymphoblastic leukemia -- Acute promyelocytic leukemia: update on risk stratification and treatment -- Current and emerging therapies for AML -- Current management and new developments in treatment of ALL -- Contemporary therapy of CML -- MDS: Pathogenesis and therapy -- Chronic lymphocytic leukemia: Biology and therapy -- Biology and current treatment of Myeloproliferative neoplasms -- Systemic Mastocytosis: Pathology and treatment -- Adoptive T-cell therapy and other novel immunotherapies for leukemia. |
| Record Nr. | UNINA-9910502610603321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2021 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Bipolar disorder : from neuroscience to treatment / / Allan H. Young, Mario F. Juruena, editors
| Bipolar disorder : from neuroscience to treatment / / Allan H. Young, Mario F. Juruena, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (viii, 325 pages) |
| Disciplina | 616.89506 |
| Collana | Current Topics in Behavioral Neurosciences |
| Soggetto topico |
Bipolar disorder - Treatment
Trastorn bipolar Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-72143-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Preface -- Contents -- The Neurobiology of Bipolar Disorder -- 1 Introduction -- 2 Neurotransmitters -- 2.1 Serotoninergic System -- 2.2 Dopaminergic System -- 2.3 Norepinephrinergic System -- 2.4 GABAergic System -- 2.5 Glutamatergic System -- 3 Intracellular Signalling -- 4 Adenylate Cyclase Signalling Pathway -- 5 Neurotrophins and Neurogenesis -- 6 Neuroendocrine -- 7 Conclusion -- References -- The Role of Stress in Bipolar Disorder -- 1 Introduction -- 1.1 Activation of Hormonal Systems After Stress -- 1.2 Stress Hormone Receptors -- 2 Stress Hormone Actions on the Brain in Healthy Individuals -- 2.1 Cellular Effects of Stress Hormones on Brain Circuits -- 2.2 Neuronal Circuits and Cognitive Function -- 3 Changes in Stress Responsiveness in Bipolar Disorder -- 3.1 Imbalance in the Stress System: Importance of Genetic and (Early) Life History -- 3.2 Changes in the HPA Axis in Bipolar Disorder Patients -- 4 Changes in Cognitive Function in Bipolar Disorder Related to Stress -- 4.1 Time-Dependent Changes in Cognitive Processing Following Stress in BD Patients -- 4.2 Network Function in BP Patients and Individuals at Risk for Psychopathology -- 5 Concluding Remarks -- References -- The Role of Genetics in Bipolar Disorder -- 1 Introduction: Why Genetics Matters in the Susceptibility to Bipolar Disorder? -- 2 Bipolar Disorder Is Heritable: Twin, Adoption, and Family Studies -- 3 How Many Genes Modulate the Risk of Bipolar Disorder? Linkage Studies, Candidate Gene Studies, and Genome-Wide Association S... -- 4 Genetic Overlap Between Bipolar Disorder and Other Brain Disorders: Disorder-Specific or General Genetic Influences? -- 5 The Role of Rare Genetic Variants -- 6 Gene x Environment Studies -- 7 Nongenetic Mechanisms Contributing to the Regulation of Gene Expression: Epigenetics -- 8 Current and Future Lines of Research.
9 Conclusion -- References -- Targeting Mitochondrial Dysfunction for Bipolar Disorder -- 1 The Mitochondria -- 1.1 Mitochondria as an Energy Source -- 1.2 Other Functions of Mitochondria -- 2 Reactive Oxygen Species and Oxidative Stress -- 3 Mitochondria in Bipolar Disorder -- 3.1 Possible Mechanisms of Mitochondrial Dysfunction in Bipolar Disorder -- 3.1.1 A Shift from OXPHOS to Glycolysis -- 3.1.2 Creatine Kinase -- 3.1.3 Calcium -- 3.1.4 Increased Oxidative Stress -- 3.1.5 Neurotransmitters -- 3.1.6 Brain-Derived Neurotrophic Factor (BDNF) -- 3.1.7 NAA -- 3.1.8 Bcl-2 -- 3.2 Mitochondrial Genes -- 4 How Conventional Drugs for Bipolar Disorder Relate to Mitochondrial Functioning -- 5 Mitochondrial Potential Treatments -- 5.1 Likely Beneficial -- 5.1.1 PPAR Agonists -- 5.1.2 Minocycline -- 5.1.3 N-Acetyl-Cysteine (NAC) -- 5.1.4 Co-enzyme Q10 -- 5.1.5 Melatonin -- 5.2 Theoretically Beneficial, but No Studies Have Been Published -- 5.2.1 Ebselen -- 5.2.2 Mangosteen -- 5.2.3 Ketogenic Diet -- 5.2.4 Resveratrol -- 5.2.5 Taurine -- 5.3 Unlikely to Be Beneficial -- 5.3.1 Alpha-Lipoic Acid (ALA) -- 5.3.2 Pyrimidines -- 5.4 Potential Risk of a Manic Switch -- 5.4.1 ALC (Acetyl-L-Carnitine) -- 5.4.2 Creatine Monohydrate (CM) -- 5.4.3 SAMe (S-Adenosyl-Methionine) -- 5.5 Vitamins -- 5.5.1 Vitamin A -- 5.5.2 Vitamin C -- 5.5.3 Vitamin D -- 5.5.4 Vitamin E -- 5.5.5 Vitamins B -- 6 Summary -- References -- Intracellular Signaling Cascades in Bipolar Disorder -- 1 Introduction -- 2 Mitochondrial Dysfunction -- 3 Calcium Channel Modulators -- 4 Intracellular Signaling and Inflammation -- 5 Glycogen Synthase Kinase 3-Beta (GSK3β) -- 6 Protein Kinase C (PKC) and Diacylglycerol (DAG) -- 7 Neurotrophins -- 8 Glutamatergic System -- 9 Dopaminergic System -- 10 Neurohormonal System -- 11 Purinergic System and Mania -- 12 Conclusion -- References. Sleep and Circadian Rhythm Disorder in Bipolar Affective Disorder -- 1 Bipolar Affective Disorder -- 2 Circadian Rhythm -- 3 Circadian Rhythm and Bipolar Affective Disorder -- 4 Circadian Rhythm Sleep-Wake Disorders -- 4.1 Delayed Sleep Phase Disorder -- 5 Genetics -- 6 Chronotype -- 7 Melatonin and Cortisol -- 8 Social Zeitgeber Theory -- 9 Circadian Rhythm and Bipolar Disorder -- 10 Conclusion -- References -- Neuroendocrine Stress System in Bipolar Disorder -- 1 Introduction -- 2 Endocrine Axis -- 2.1 Regulation of the Hypothalamic-Pituitary-Adrenal Axis -- 2.2 The Glucocorticoid Receptor (GR) -- 2.3 Mineralocorticoid Receptors (MRs) -- 2.4 Molecular Mechanisms for Resistance of Glucocorticoid Receptors -- 3 Abnormalities of the HPA Axis in Depression -- 3.1 Impact of Stress on Bipolar Disorders -- 3.2 Impact of Mediating Factors on the HPA Axis -- 4 Factors Associated with an Endophenotype Increasing Vulnerability -- 5 Conclusion -- References -- Neuroanatomic and Functional Neuroimaging Findings -- 1 Introduction -- 2 Structural Neuroimaging and Diffusion Tensor Imaging Studies -- 2.1 Structural Magnetic Resonance Imaging MRI (sMRI) Findings in BD -- 2.2 Diffusion Tensor Imaging (DTI) Findings in BD -- 2.3 Longitudinal sMRI and DTI Findings -- 3 Functional Neuroimaging -- 3.1 Positron Emission Tomography (PET) -- 3.2 Resting-State Functional MRI (rsfMRI) -- 4 Summary of Main Findings -- 5 Diagnostic Specificity of Neuroimaging Findings -- 5.1 Structural Neuroimaging and DTI Findings -- 5.2 Functional Neuroimaging Findings (PET, rs-fMRI) -- 5.3 Neuroimaging and Pattern Classification Methods and the Diagnosis of BD -- 6 Perspectives on the Role of Neuroimaging in the Management of BD Patients -- 6.1 Neuroimaging Studies and Bipolar Disorders Mood States -- 6.2 Neuroimaging Studies, Bipolar Disorders, and Pharmacological Treatment. 6.3 Neuroimaging to Predict Pharmacological Treatment Response -- 6.4 Neuroimaging and Psychotherapy in Bipolar Disorders -- 7 Conclusions -- References -- Structural and Functional Brain Correlates of Neuroprogression in Bipolar Disorder -- 1 Introduction -- 2 Structural Aspects of Neuroprogression in Neuroimaging -- 2.1 Evidence from Cross-Sectional Studies -- 2.1.1 Brain Volume and General Findings -- 2.1.2 Prefrontal Cerebral Cortex -- 2.1.3 Cingulate Cortex -- 2.1.4 Temporal-Limbic Structures -- 2.1.5 Other Brain Structures -- 2.2 Evidence from Longitudinal Studies -- 2.2.1 Brain Volume and General Findings -- 2.2.2 Prefrontal Cerebral Cortex -- 2.2.3 Cingulate Cortex -- 2.2.4 Temporal-Limbic Structures -- 3 Functional Aspects of Neuroprogression in Neuroimaging -- 4 Challenges (Limitations) and Perspectives -- References -- Inflammation as a Mechanism of Bipolar Disorder Neuroprogression -- 1 Introduction -- 2 Evidence of Inflammatory and Infectious Diseases in BD Neuroprogression -- 2.1 Maternal Immune Activation as a Risk Factor for BD Development and Neuroprogression -- 2.2 Role of Infectious Disease as a Trigger to Develop BD Neuroprogression -- 2.3 Autoimmune Disorders and Their Association with BD Neuroprogression -- 2.4 Role of the Gut-Brain Axis on BD Neuroprogression -- 3 Inflammatory and Oxidative Mechanisms in BD Neuroprogression -- 3.1 Mechanisms of Inflammation and Their Contribution to BD Neuroprogression -- 3.2 Oxidative Stress and Mitochondrial Dysfunction Associated with BD Neuroprogression -- 3.3 Peripheral Inflammatory Mediators as a Trigger or Accelerator of BD Neuroprogression -- 3.4 Cerebrospinal Fluid (CSF) System Inflammatory Markers in BD Neuroprogression -- 3.5 Postmortem Inflammatory Markers in BD Neuroprogression -- 4 Conclusions and Future Directions -- References -- Neuropsychology of Bipolar Disorder. 1 Pattern and Magnitude of Impairment -- 2 What Are the Factors that Affect Cognition? -- 2.1 Diagnostic Features -- 2.2 Sleep -- 2.3 Physical Health -- 2.4 Medication -- 3 Summary -- 4 Methods of Assessment -- 4.1 Longitudinal Changes -- 4.2 Identifying Neuropsychological Phenotypic Clusters -- 4.3 Hierarchical Organization of Cognition -- 4.4 Experimental Analysis Methods -- 5 Conclusions -- References -- The Kindling/Sensitization Model and Early Life Stress -- 1 Introduction -- 2 Stress Sensitization -- 3 Stimulant-Induced Behavioral Sensitization -- 4 Episode-Induced Sensitization -- 5 Cross-Sensitization: Neurochemical Commonalities and Inflammatory Mechanisms -- 6 An Epigenetic Basis for Sensitization -- 7 One Genetic and Two Epigenetic Bases for Illness Vulnerability -- 8 More Stress, Episodes, and Substance Abuse in the USA Than Europe Driving Sensitization -- 9 Implications for Treatment -- 10 High Risk Children Deserve Special Attention and Treatment -- 11 Measures Considered for Primary and Secondary Prevention -- 12 Conclusions -- References -- Childhood Maltreatment in Bipolar Disorders -- 1 Introduction -- 2 Childhood Maltreatment and (More Severe) Bipolar Disorders -- 2.1 Childhood Maltreatment as a Risk Factor for Developing Bipolar Disorders -- 2.2 Childhood Maltreatment and the Severity of the Clinical Expression of Bipolar Disorders -- 2.3 Childhood Maltreatment, Psychiatric, and Medical Comorbidities in Bipolar Disorders -- 2.4 Issues About Childhood Maltreatment Subtypes, the Timing of Exposure, and Gender -- 3 Moving to Dimensions of Psychopathology in Association with Childhood Maltreatment -- 3.1 Childhood Maltreatment and Dimensions of Psychopathology in Bipolar Disorders -- 3.2 Childhood Maltreatment and Cognition in Bipolar Disorders -- 4 Childhood Maltreatment as Part of a Multiple Hit Model of Susceptibility. 4.1 Interactions Between Childhood Maltreatment and the Genetic Susceptibility to Bipolar Disorders. |
| Record Nr. | UNINA-9910485147503321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Breast cancer, from bench to personalized medicine / / edited by Saima Shakil Malik and Nosheen Masood
| Breast cancer, from bench to personalized medicine / / edited by Saima Shakil Malik and Nosheen Masood |
| Pubbl/distr/stampa | Gateway East, Singapore : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (534 pages) |
| Disciplina | 616.9449 |
| Soggetto topico |
Breast - Cancer - Treatment
Breast - Cancer Càncer de mama Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-19-0197-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Foreword -- Preface -- Acknowledgment -- Contents -- About the Editors -- Part I: Overview of Breast Cancer -- 1: Epidemiology and Risk Factors of Breast Cancer -- 1.1 Introduction -- 1.1.1 Invasive Ductal Carcinoma -- 1.1.2 Invasive Lobular Carcinoma -- 1.2 Morphological and Molecular Classification of Breast Tumors -- 1.2.1 Morphological Classification -- 1.2.2 Molecular Classification -- 1.3 Global Distribution and Epidemiology of Breast Cancer -- 1.4 Risk Factors Influencing Tumor Behavior -- 1.4.1 Genetic Factors -- 1.4.1.1 BRCA -- 1.4.1.2 PALB2 -- 1.4.1.3 TP53 -- 1.4.1.4 ATM -- 1.4.1.5 CDH1 -- 1.4.1.6 CHEK2 -- 1.4.1.7 STK11 -- 1.4.1.8 NF1 -- 1.4.1.9 NBN -- 1.4.2 Epigenetic Factors -- 1.4.3 Demographic Factors -- 1.4.4 Blood Group -- 1.4.5 Reproductive Factors -- 1.4.5.1 Menarche Age -- 1.4.5.2 Full-Term Pregnancy -- 1.4.5.3 Abortion -- 1.4.5.4 Menstrual Cycle -- 1.4.6 Endocrine Factors -- 1.4.6.1 Contraceptive Methods -- 1.4.6.2 Ovulation-Stimulating Drugs -- 1.4.6.3 Postmenopausal Hormone Therapy -- 1.4.7 Family History -- 1.4.8 Breast Density and Lactation -- 1.4.9 Environmental Factors -- 1.4.9.1 Environmental Factors -- 1.4.9.2 Radiation -- 1.4.9.3 Exposure to Various Chemicals -- 1.4.9.4 Lifestyle Factors -- 1.4.9.5 Body Mass Index (BMI) -- 1.4.9.6 Hyperglycemia -- 1.4.9.7 Alcohol Consumption -- 1.4.9.8 Smoking -- 1.4.9.9 Diet -- 1.4.9.10 Sleep Patterns -- 1.4.9.11 Caffeine -- 1.4.9.12 Physical Activity -- 1.4.9.13 Vitamin D -- 1.4.9.14 Socioeconomic Status -- 1.5 Prevention Strategies and Treatments for Breast Cancer -- 1.6 Conclusion -- References -- 2: Histopathological Characteristics: Breast Cancer Subtypes Depending on Receptor Status, Clinical and Pathological Staging o... -- 2.1 Introduction -- 2.2 Histological Classification of Breast Cancer -- 2.2.1 Invasive Breast Cancer -- 2.2.1.1 Invasive Ductal Carcinoma.
2.2.1.1.1 Medullary Breast Carcinoma -- Histological Organization of Medullary Breast Carcinoma -- 2.2.1.1.2 Metaplastic Carcinoma -- Histological Organization of Metaplastic Breast Cancer -- 2.2.1.1.3 Adenoid Cystic Carcinoma -- Histological Organization of Adenoid Cystic Carcinoma of Breast -- 2.2.1.1.4 Mucinous Carcinoma -- Histological Organization of Mucinous Carcinoma -- 2.2.1.1.5 Tubular Carcinoma -- Histological Organization of Tubular Carcinoma -- 2.2.1.1.6 Carcinoma with Papillary Morphology -- Histological Organization of Papillary Carcinoma -- 2.2.1.1.7 Apocrine Carcinoma (Androgen-Receptor Positive and Estrogen-Receptor Negative) -- Histological Organization of Apocrine Carcinoma -- 2.2.1.1.8 Neuroendocrine Carcinoma -- Histological Organization of Neuroendocrine Carcinoma -- 2.2.1.2 Invasive Lobular Carcinoma -- 2.2.1.2.1 Histological Organization of Invasive Lobular Carcinoma. -- 2.3 Conclusion -- References -- 3: Relationship of Breast Cancer with Other Hormone-Sensitive Cancers -- 3.1 Introduction -- 3.2 Role of Hormones in Breast Cancer -- 3.2.1 Tumor-Promoting Effects of Estrogen -- 3.2.2 Tumor-Promoting Effects of Progesterone -- 3.2.3 Melatonin and Hormone-Dependent Breast Cancer -- 3.2.4 Hormonal Contraception and Breast Cancer -- 3.2.5 Menopause Hormone Therapy and Breast Cancer -- 3.3 Relation Between Breast Cancer and Other Hormones Related to Cancer -- 3.3.1 Different Hormones Sensitive Cancers -- 3.3.2 Breast Cancer and Ovarian Cancer -- 3.3.3 Breast Cancer and Endometrial Cancer -- 3.4 Biomarkers in Breast and OHRC -- 3.4.1 N1-Acetylspermidine as a Chemical Biomarker -- 3.4.2 Mucin-1, Urokinase-Type Plasminogen Activator as Protein Biomarker -- 3.4.3 Ki-67 as a Prophetic Marker in Breast Cancer -- 3.4.4 HER2 as a Prophetic Marker in Breast Cancer -- 3.5 Genetics Behind Hormonal Breast Cancer. 3.5.1 BRCA1 and BRCA2 Gene Mutation -- 3.5.2 High Menace Gene Mutations in PALB2, PTEN, and TP53 Genes -- 3.5.3 Moderate Menace Gene Mutations in ATM and cdh1genes -- 3.5.4 Less Risk Gene Mutations in CHEK2, NBN, NF1, and STK11 Genes -- 3.6 Conclusion -- References -- 4: Cancer Care and Psychosocial Needs -- 4.1 Introduction -- 4.1.1 Death and Survival Rates -- 4.1.2 Risk Factors -- 4.1.2.1 Inherent Risk Factors -- 4.1.2.2 Environmental Factors -- 4.1.2.3 Behavioral Risk Factors -- 4.2 Living with Cancer -- 4.2.1 Adjusting to Diagnosis and Treatment -- 4.3 Cancer Induced Stressor -- 4.3.1 Psychosocial Stressors -- 4.3.2 Consequences of Stressors -- 4.4 Psychosocial Aspects of Cancer -- 4.4.1 Social Support -- 4.4.2 Communication -- 4.4.3 Management of Psychosocial Aspects -- 4.4.4 Psychotherapy with Cancer Patients -- References -- Part II: Cell and Molecular Biology of Breast Cancer (Diagnosis and Prognosis) -- 5: Implications of BRCA1, BRCA2 Gene in Overall Development and Prognosis of Breast Cancer -- 5.1 Introduction -- 5.1.1 Genes Related to Breast Cancer -- 5.2 Importance of Detection of BRCA Mutations -- 5.3 Pathology of BRCA1 and BRCA2 Associated Breast Cancers -- 5.3.1 BRCA-1 and BRCA-2 Probability Models -- 5.3.2 BOADICEA Model -- 5.3.3 BRCAPRO Model -- 5.3.4 Couch Model -- 5.3.5 Manchester Model -- 5.3.6 Myriad Model -- 5.3.7 Tyrer-Cuzick Model -- 5.4 Implication of BRCA1/2 in Hereditarily Onset of Breast Cancer -- 5.5 Advantages and Disadvantages of Screening and Genetic Testing -- 5.5.1 Advantages of Screening and Genetic Testing -- 5.5.2 Disadvantages of Screening and Genetic Testing -- 5.6 Future Perspective -- References -- 6: Early-Stage Progression of Breast Cancer -- 6.1 Early-Stage Progression of Breast Cancer -- 6.2 Epigenetics in Breast Cancer Progression -- 6.3 Molecular Classification of Breast Cancer. 6.4 ERPT Positive Group: Luminal Type -- 6.5 ERNT Negative Group -- 6.5.1 HER2 Enriched Subclass -- 6.5.2 Breast Like -- 6.5.3 Basal Like -- 6.6 Progression of Breast Cancer and Role of Cell Specific Polarity Proteins -- 6.7 Role of High and Low Penetrance Genes -- 6.8 High Penetrance Breast Cancer Genes -- 6.9 BRCA1 and BRCA2 -- 6.9.1 PALB2 -- 6.9.2 TP53 -- 6.9.3 PTEN -- 6.9.4 STK11 -- 6.9.5 CDH1 -- 6.10 Low Penetrance Breast Cancer Genes -- References -- 7: Noninvasive Biomarkers: Emerging Trends in Early Detection of Breast Cancer -- 7.1 Introduction -- 7.2 Types of Noninvasive Biomarkers -- 7.2.1 Blood-Based Biomarker -- 7.2.1.1 Circulating Carcinoma Proteins -- 7.2.1.2 Circulating Tumor Cells -- 7.2.1.3 Circulating Cell-Free Tumor DNA -- 7.2.1.4 Circulating miRNAs -- 7.2.1.5 Extracellular Vesicles -- 7.2.1.6 Other Blood-Based Biomarkers -- 7.2.2 Non-blood-Based Biomarkers -- 7.2.2.1 Tears -- 7.2.2.2 Breath -- 7.2.2.3 Nipple Aspirate Fluid -- 7.2.2.4 Apocrine Sweat -- 7.2.2.5 Urine -- 7.3 Biomarkers Involved in Cancer Progression/Proliferation -- 7.3.1 circRNAs -- 7.3.2 miRNAs -- 7.4 Biomarkers Involved in Cancer Metastasis -- 7.4.1 miRNAs -- 7.4.2 Chemokines -- 7.5 Biomarkers Involved in Cancer Drug Resistance -- 7.5.1 circRNA -- 7.5.2 miRNA -- 7.6 Progress of Breast Cancer Biomarker Research: Limitations, Challenges, and Future Perspective -- 7.7 Conclusion -- References -- 8: Epigenetics Involvement in Breast Cancer -- 8.1 Introduction -- 8.2 Epigenetics and Breast Cancer -- 8.3 Epigenetic Mechanisms in the Breast Cancer -- 8.3.1 DNA Methylation -- 8.3.2 Histone Modifications -- 8.3.3 Non-coding RNAs (ncRNAs) -- 8.4 Epigenetics as a Diagnostic Tool for Breast Cancer -- 8.4.1 DNA Methylation as Potential Diagnostic Biomarker -- 8.4.2 Non-coding RNAs as Potential Diagnostic Biomarker -- 8.5 Epigenetics as Predictive Biomarkers. 8.5.1 DNA Methylation as Predictive Markers -- 8.5.2 Histone Modifications as Predictive Biomarkers -- 8.5.3 ncRNAs as Potential Predictive Biomarkers -- 8.6 Epigenetics as Prognostic Markers in Breast Cancer -- 8.6.1 DNA Methylation as a Prognostic Biomarker -- 8.6.2 Histone Modification as a Biomarker -- 8.6.3 Non-coding RNAs as Prognostic Biomarkers -- 8.7 Epigenetics Modifications as Therapeutic Target -- 8.8 Conclusion -- References -- 9: Role of Fibrinolytic Mechanisms in Breast Cancer Diagnosis, Prognosis, and Treatment -- 9.1 Introduction: Fibrinolysis and Fibrinolytic System -- 9.2 Breast Cancer Etiology -- 9.3 Pathologies Associated with Fibrinolytic System in Breast Cancer -- 9.3.1 Breast Cancer Progression and Role of Hemostatic Function -- 9.4 Components of Fibrinolytic System -- 9.4.1 Plasminogen and Plasmin -- 9.4.2 Thrombin -- 9.4.3 Tissue Factors -- 9.5 Fibrinolytic System as Diagnostic Target -- 9.5.1 Prognostic Biomarkers -- 9.5.2 Diagnostic Biomarkers -- 9.6 Fibrinolytic System as Therapeutic Target -- 9.6.1 Inhibitors of Coagulation -- 9.6.2 Transcriptional Repression -- 9.6.3 Small Molecules and Epigenetic Agents -- 9.6.4 Toxin Conjugates -- 9.6.5 Antibodies -- 9.6.6 Peptide Inhibitors -- 9.6.7 Natural and Chemical Products -- 9.6.8 Aptamers -- 9.7 Conclusion and Future Directions -- References -- 10: MicroRNAs and Noncoding RNAs as Gene Regulators and Potential Therapeutic Agents -- 10.1 Introduction -- 10.2 Biogenesis of miRNA -- 10.2.1 Canonical Pathway Aimed at miRNA Biogenesis -- 10.2.2 Non-canonical Pathway Aimed at miRNA Biogenesis -- 10.3 MicroRNAs as a Gene Regulator -- 10.3.1 MicroRNAs Mediated Gene Silencing -- 10.3.2 MicroRNA-Mediated Translational Activation -- 10.4 Significance of Noncoding RNA into the Breast Cancer -- 10.4.1 miRNA and Breast Cancer -- 10.4.1.1 miRNAs Serve as a Tumor Suppressor. 10.4.1.1.1 Let-7 Family. |
| Record Nr. | UNINA-9910568287503321 |
| Gateway East, Singapore : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
